title: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
abstract: Although nonalcoholic steatohepatitis (NASH) has generally been considered a benign condition, the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease. The aim of this study is to determine the frequency, clinical features, and posttransplantation history of decompensated liver disease secondary to NASH. The frequency of NASH as a cause of end-stage liver disease was prospectively determined in patients evaluated for liver transplantation. NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded. Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period, 31 patients (2.6%) had NASH as the primary cause of liver disease. In the same period, 546 liver transplantations were performed, 16 of which (2.9%) were for end-stage disease secondary to NASH. Posttransplantation steatosis was seen in 60% of transplant recipients with NASH versus 5% of those with cholestatic disease, 15% of those with alcoholic disease, and 15% of those with hepatitis C. Steatohepatitis recurred in 33% of transplant recipients with NASH, with progression to cirrhosis in 12.5%. NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9% of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation.
authors.affiliation: Liver Transplant Unit, Mayo Clinic, Rochester, MN 55905, USA. charlton.m@mayo.edu
authors.forename: M
authors.initials: M
authors.lastname: Charlton
authors.forename: P
authors.initials: P
authors.lastname: Kasparova
authors.forename: S
authors.initials: S
authors.lastname: Weston
authors.forename: K
authors.initials: K
authors.lastname: Lindor
authors.forename: Y
authors.initials: Y
authors.lastname: Maor-Kendler
authors.forename: R H
authors.initials: RH
authors.lastname: Wiesner
authors.forename: C B
authors.initials: CB
authors.lastname: Rosen
authors.forename: K P
authors.initials: KP
authors.lastname: Batts
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D005234:Fatty Liver / Q000150:complications* / Q000473:pathology; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000473:pathology; D017093:Liver Failure / Q000209:etiology* / Q000473:pathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications